Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EFTR - eFFECTOR Therapeutics, Inc.

Previous close
0.1891
-11.761   -6,219.408%

Share volume: 0
Last Updated: Tue 02 Jul 2024 08:03:49 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$11.95
-11.76
-98.42%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 18%
Dept financing 25%
Liquidity 34%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
1.35%
6 Months
-86.11%
1 Year
-99.67%
2 Year
-91.07%
Key data
Stock price
$0.19
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$0.75
52 WEEK RANGE
$0.04 - $17.75
52 WEEK CHANGE
-$99.67
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.420 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Stephen T. Worland
Region: US
Website: effector.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

eFFECTOR Therapeutics, Inc. engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E)

Recent news